Tirzepatide 30mg
Bulk Format — Extended Protocol Supply
Double the standard 15mg vial in a single container. The most practical bulk format for researchers at maintenance dosing who need supply continuity without repeat ordering.
Starting From
$279.99
Sold By
Apollo Peptide Sciences
Suggested Protocol
For researchers at established maintenance dose of 10–15mg weekly. Reconstitute with 2–3ml bacteriostatic water for a working concentration of 10–15mg/ml. SubQ injection once weekly. Store reconstituted vial refrigerated; draw from the same vial across multiple weeks of dosing.
22.5%
Body Wt. Loss
2–3 wks
Duration
Bulk 30 mg
Format
Fewer Vials, More Continuity — The Operational Case for Bulk Tirzepatide Format
The 30mg tirzepatide vial delivers exactly double the compound volume of the standard 15mg vial in a single unit — designed for researchers who have established their maintenance dose and need extended supply without the friction of frequent reordering. At 10–15mg weekly maintenance dosing, a single 30mg vial provides approximately 2–3 weeks of uninterrupted research supply, making it the preferred format for sustained protocols.
Tirzepatide's dual GLP-1/GIP mechanism — responsible for the SURMOUNT-1 trial's landmark 22.5% body weight reduction — is at its most consistently expressed during long, uninterrupted maintenance-phase research. Protocol interruptions caused by vial shortages compromise both research continuity and the sustained hormonal signaling environment that produces tirzepatide's cumulative metabolic effects. The 30mg format directly addresses this operational risk.
The economics are compelling: the 30mg vial costs meaningfully less per milligram than two individual 15mg vials, and the reduction in reconstitution events cuts both handling time and the cumulative contamination risk that comes with managing multiple vials across a multi-week protocol. For researchers running tirzepatide as a primary fat loss compound — rather than a starter protocol — the 30mg vial is the natural operating format.
Paired with bacteriostatic water for reconstitution, the 30mg vial accommodates precise concentration targeting regardless of the researcher's specific maintenance dose within the 10–15mg weekly range. Whether the target is 10mg (yielding 3 weeks of supply) or 15mg (yielding 2 weeks), a single vial covers the full interval cleanly.
The Reconstitution Argument
Why Every Additional Vial Opening Is a Point of Failure — and How the 30mg Reduces Them
Each time you reconstitute a new vial, you introduce a handling event: piercing the septum, injecting bacteriostatic water, swirling to dissolve, drawing the solution. Each step is an opportunity for measurement error, contamination, or degradation from excessive agitation. Two 15mg vials require two separate reconstitutions to cover the same compound volume as one 30mg vial. Over a multi-month protocol, those extra handling events accumulate. The 30mg vial cuts reconstitution frequency in half — and at 2–3 weeks of supply per vial at maintenance dosing, it means changing vials roughly twice per month instead of every week.
What 2–3 Weeks of Single-Vial Supply Means Practically
Protocol Simplicity: One Vial, Multiple Doses, Consistent Concentration Throughout
Once a 30mg vial is reconstituted to your target concentration, every dose drawn from it is from the same solution — same concentration, same stability profile, same preparation. This is actually preferable to switching vials mid-protocol, where you're opening a new vial, reconstituting fresh, and potentially introducing slight concentration differences. A single reconstituted 30mg vial supports 2–3 consecutive weekly injections from one stable, precisely prepared source — which is as operationally clean as single-vial tirzepatide management gets.
The Step Between 15mg and 60mg
Why the 30mg Format Is the Right Commitment Level for Established Protocols
The 15mg vial is the right starting format for researchers who haven't yet confirmed their exact maintenance dose. The 60mg bulk format is the right format for researchers executing extended 4–6 week single-vial protocols. The 30mg occupies the middle ground: you've confirmed your protocol, you're not ready to commit to the full bulk format, but you want meaningfully more continuity and better economics than the standard 15mg vial provides. It's the format for researchers who know tirzepatide works for them and are optimizing their supply logistics accordingly.
Key Benefits
2x the volume of the standard 15mg vial in a single unit
Lower cost per milligram than two separate 15mg vials
Provides 2–3 weeks of supply at 10–15mg weekly maintenance dosing
Reduces reconstitution frequency and associated handling risk
Eliminates mid-protocol supply gaps that compromise research continuity
Ideal for researchers who have established tirzepatide tolerability and maintenance dose
Fewer total vials to track, store, and manage across extended protocols
Best value entry point for bulk tirzepatide research supply
Full Protocol
For researchers at established maintenance dose of 10–15mg weekly. Reconstitute with 2–3ml bacteriostatic water for a working concentration of 10–15mg/ml. SubQ injection once weekly. Store reconstituted vial refrigerated; draw from the same vial across multiple weeks of dosing.
Best Stacked With
More in Weight Management
View All
Semaglutide
The compound behind Ozempic/Wegovy. GLP-1 receptor agonist producing significant appetite suppression, fat loss, and metabolic improvement with once-weekly dosing.
